Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Q2 2024 Results Conference Call August 8, 2024 4:30 PM ET Company Participants Gayathri Diwakar - Head of Investor Relations Scott Struthers - Founder and Chief Executive Officer Dana Pizzuti - Chief Medical and Development Officer Jim Hassard - Chief Commercial Officer Marc Wilson - Chief Financial Officer Alan Krasner - Chief Endocrinologist Conference Call Participants Jessica Fye - JPMorgan Yasmeen Rahimi - Piper Sandler Jeff Hung - Morgan Stanley Dennis Din ...

Crinetics Pharmaceuticals, Inc. (CRNX) came out with a quarterly loss of $0.94 per share versus the Zacks Consensus Estimate of a loss of $0.86. This compares to loss of $0.94 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -9.30%. A quarter ago, it was expected that this company would post a loss of $0.84 per share when it actually produced a loss of $0.93, delivering a surprise of -10.71%. Over the last four quarters, the c ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38583 Crinetics Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 26-3744114 (State or other ju ...

The market expects Crinetics Pharmaceuticals, Inc. (CRNX) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2024. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates. The earnings report, which is expected to be released on August 8, 2024, might help the stock move higher if the ...

SAN DIEGO, July 18, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report second quarter 2024 financial results on Thursday, August 8, 2024 after the market closes. Company management will host a conference call at 4:30 p.m. ET that day to discuss financial results and provide a business update. Conference Call & Webcast | --- | --- | |----------------|-----------------------------------| | | | | | | | | Thursday, August 8th @ 4:30 PM ET | | Domestic: | ...

The 2021 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Crinetics, or following a bona fide period of non-employment, as an inducement material to such individuals' entering into employment with Crinetics, pursuant to Nasdaq Listing Rule 5635(c) (4). The options have an exercise price of $50.80 per share, which is equal to the closing price of Crinetics' common stock on The Nasdaq Global Select Market on July 10, 2024. The shares subjec ...

Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors. Crinetics was founded in 2008 based on a vision to transform how endocrine diseases are treated. Today, the company is well positioned to deliver on this vision with a strong business, propelled by its lead drug candidate paltusotine which is on track for a New Drug Application submission with the U.S. Foo ...

Core Insights - Scott Struthers, Ph.D., founder and CEO of Crinetics Pharmaceuticals, has been awarded the Entrepreneur Of The Year® 2024 Pacific Southwest Award, recognizing his leadership in high-growth companies [1][4]. Company Overview - Crinetics Pharmaceuticals is a clinical-stage pharmaceutical company focused on discovering, developing, and commercializing novel therapeutics for endocrine diseases and endocrine-related tumors [3][16]. - The company was founded in 2008 and has grown to over 300 employees, emphasizing a collaborative approach to innovation in treatment [3]. - Crinetics is advancing its lead drug candidate, paltusotine, which is expected to submit a New Drug Application to the FDA by the end of 2024 [3][16]. - The company has a robust pipeline of internally discovered drug candidates targeting various endocrine conditions, including acromegaly and congenital adrenal hyperplasia [16]. Awards and Recognition - As a Pacific Southwest award winner, Dr. Struthers is eligible for the Entrepreneur Of The Year 2024 National Awards, with winners announced in November [4]. - The Entrepreneur Of The Year program has recognized over 11,000 entrepreneurs since its inception in 1986, expanding to nearly 80 countries [8].

"The depth and breadth of our clinical development program for once-daily, oral paltusotine under investigation for the treatment of acromegaly is on display at ENDO 2024, demonstrating its rapid, durable effect on both biochemical and symptom control in these studies," said Scott Struthers, Ph.D., founder and chief executive officer of Crinetics. "Notably, based on patient reported outcome data captured daily by the Acromegaly Symptom Diary, a new analysis from the PATHFNDR-1 trial showed that paltusotine ...

Core Insights - Crinetics Pharmaceuticals announced promising initial findings from its clinical product candidate, atumelnant (CRN04894), a novel oral ACTH receptor antagonist, during the Endocrine Society's annual meeting (ENDO2024) [1][2] Group 1: Clinical Trial Results - In the Phase 2 TouCAHn study, participants with congenital adrenal hyperplasia (CAH) showed over 90% reduction in androstenedione (A4) and 97% reduction in 17-hydroxyprogesterone (17-OHP) after 12 weeks of treatment with atumelnant (80 mg) [1][3] - 100% of CAH participants maintained A4 levels below the upper limit of normal at all time points during the treatment [1][3] - The Phase 1b/2a study for ACTH-dependent Cushing's syndrome demonstrated that 100% of participants achieved serum cortisol levels below 5 mcg/dL within 10 days of atumelnant administration [6][9] Group 2: Safety and Tolerability - No severe or serious treatment-emergent adverse events were reported in the ongoing trials, with all adverse events being mild to moderate [4][6] - The most common treatment-emergent adverse events included fatigue, headache, and upper respiratory tract infection [4][6] Group 3: Mechanism and Significance - Atumelnant is the first once-daily oral ACTH receptor antagonist, which directly inhibits ACTH at its receptor, offering a novel approach compared to traditional glucocorticoid treatments [2][5] - The drug has shown strong binding affinity for the melanocortin type 2 receptor (MC2R) and effectively suppresses adrenally derived glucocorticoids and androgens [11] Group 4: Future Developments - The TouCAHn study aims to enroll up to 30 patients and is ongoing, with topline results expected in the second half of 2024 [12] - Crinetics will host an investor conference call to discuss these findings further [7]